4 Stocks Advancing The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 15 points (0.1%) at 16,035 as of Monday, Dec. 9, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,480 issues advancing vs. 1,397 declining with 175 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.3%. Top gainers within the sector include Celgene Corporation ( CELG), up 4.2%, Bristol-Myers Squibb Company ( BMY), up 1.9%, Gilead ( GILD), up 1.3%, Cigna ( CI), up 1.2% and WellPoint ( WLP), up 1.0%. On the negative front, top decliners within the sector include Edwards Life ( EW), down 5.6%, and Biogen Idec ( BIIB), down 0.8%.

TheStreet would like to highlight 4 stocks pushing the sector higher today:

4. DaVita HealthCare Partners ( DVA) is one of the companies pushing the Health Care sector higher today. As of noon trading, DaVita HealthCare Partners is up $2.51 (4.3%) to $60.77 on heavy volume. Thus far, 1.9 million shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $58.47-$60.84 after having opened the day at $58.48 as compared to the previous trading day's close of $58.26.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $12.1 billion and is part of the health services industry. The company has a P/E ratio of 21.5, above the S&P 500 P/E ratio of 17.7. Shares are up 3.4% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Valeant Pharmaceuticals International ( VRX) is up $0.62 (0.6%) to $108.29 on average volume. Thus far, 481,328 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $107.03-$108.63 after having opened the day at $108.03 as compared to the previous trading day's close of $107.67.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $35.4 billion and is part of the drugs industry. Shares are up 80.1% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Alexion Pharmaceuticals ( ALXN) is up $1.10 (0.9%) to $126.55 on heavy volume. Thus far, 754,705 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 985,400 shares. The stock has ranged in price between $126.00-$128.09 after having opened the day at $127.14 as compared to the previous trading day's close of $125.45.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $24.0 billion and is part of the drugs industry. The company has a P/E ratio of 69.0, above the S&P 500 P/E ratio of 17.7. Shares are up 30.3% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Alexion Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Eli Lilly and Company ( LLY) is up $0.26 (0.5%) to $50.88 on light volume. Thus far, 1.3 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 6.3 million shares. The stock has ranged in price between $50.49-$50.95 after having opened the day at $50.58 as compared to the previous trading day's close of $50.63.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $56.3 billion and is part of the drugs industry. The company has a P/E ratio of 11.4, below the S&P 500 P/E ratio of 17.7. Shares are up 1.3% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%